Cargando…

Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab

BACKGROUND: Spontaneous regression of metastatic melanoma and delayed responses more than one year after treatment with ipilimumab are rarely seen. CASE PRESENTATION: Here, we present the case of a patient with in transit metastases from cutaneous melanoma on his right lower extremity who achieved c...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreira, Raphael B., Hamieh, Lana, Gjini, Evisa, Lako, Ana, Krajewski, Katherine M., Yoon, Charles H., Ott, Patrick A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514538/
https://www.ncbi.nlm.nih.gov/pubmed/28716097
http://dx.doi.org/10.1186/s40425-017-0259-9
_version_ 1783250860261769216
author Moreira, Raphael B.
Hamieh, Lana
Gjini, Evisa
Lako, Ana
Krajewski, Katherine M.
Yoon, Charles H.
Ott, Patrick A.
author_facet Moreira, Raphael B.
Hamieh, Lana
Gjini, Evisa
Lako, Ana
Krajewski, Katherine M.
Yoon, Charles H.
Ott, Patrick A.
author_sort Moreira, Raphael B.
collection PubMed
description BACKGROUND: Spontaneous regression of metastatic melanoma and delayed responses more than one year after treatment with ipilimumab are rarely seen. CASE PRESENTATION: Here, we present the case of a patient with in transit metastases from cutaneous melanoma on his right lower extremity who achieved complete regression of all metastatic lesions 13 months after the first of two consecutive palliative resections of dominant masses and more than two years after treatment with ipilimumab. CONCLUSION: The exact cause of our patient’s sudden onset of tumor regression remains speculative. We hypothesize that the operative trauma followed by the postoperative infections augmented an innate immune response.
format Online
Article
Text
id pubmed-5514538
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55145382017-07-19 Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab Moreira, Raphael B. Hamieh, Lana Gjini, Evisa Lako, Ana Krajewski, Katherine M. Yoon, Charles H. Ott, Patrick A. J Immunother Cancer Case Report BACKGROUND: Spontaneous regression of metastatic melanoma and delayed responses more than one year after treatment with ipilimumab are rarely seen. CASE PRESENTATION: Here, we present the case of a patient with in transit metastases from cutaneous melanoma on his right lower extremity who achieved complete regression of all metastatic lesions 13 months after the first of two consecutive palliative resections of dominant masses and more than two years after treatment with ipilimumab. CONCLUSION: The exact cause of our patient’s sudden onset of tumor regression remains speculative. We hypothesize that the operative trauma followed by the postoperative infections augmented an innate immune response. BioMed Central 2017-07-18 /pmc/articles/PMC5514538/ /pubmed/28716097 http://dx.doi.org/10.1186/s40425-017-0259-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Moreira, Raphael B.
Hamieh, Lana
Gjini, Evisa
Lako, Ana
Krajewski, Katherine M.
Yoon, Charles H.
Ott, Patrick A.
Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
title Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
title_full Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
title_fullStr Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
title_full_unstemmed Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
title_short Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
title_sort regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514538/
https://www.ncbi.nlm.nih.gov/pubmed/28716097
http://dx.doi.org/10.1186/s40425-017-0259-9
work_keys_str_mv AT moreiraraphaelb regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab
AT hamiehlana regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab
AT gjinievisa regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab
AT lakoana regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab
AT krajewskikatherinem regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab
AT yooncharlesh regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab
AT ottpatricka regressionofmultifocoalintransitmelanomametastasesafterpalliativeresectionofdominantmassesand2yearsaftertreatmentwithipilimumab